Abstract: Agents and methods for treating, reducing or ameliorating pathological fibrosis and disease or disorders caused by or associated with excessive deposition of fibrous tissue, and methods of identifying suitable agents. Preferred agents modulate the level and/or activity of GPR124.

Abstract: Agents and methods for treating, reducing or ameliorating pathological fibrosis and disease or disorders caused by or associated with excessive deposition of fibrous tissue, and methods of identifying suitable agents. Preferred agents modulate the level and/or activity of GPR124.

Abstract: A liquid-transport device has a liquid-tight support (12) on which there is applied a start zone (24; 24?) for applying transport liquid to be transported and a target zone (26, 28; 26a-e) into which the transport liquid is to be transported and also a conduction zone that extends between the start zone (24, 24?) and the target zone (26, 28; 26a-e) and that has a microporous transport layer (14) in which the transport liquid flows by capillary force from the start zone (24; 24?) to the target zone (26, 28; 26a-e). The conduction zone has a multiplicity of open flow channels separated from one another by microporous bridges having open-pored side walls.

Abstract: A liquid-transport device has a liquid-tight support (12) on which there is applied a start zone (24; 24?) for applying transport liquid to be transported and a target zone (26, 28; 26a-e) into which the transport liquid is to be transported and also a conduction zone that extends between the start zone (24, 24?) and the target zone (26, 28; 26a-e) and that has a microporous transport layer (14) in which the transport liquid flows by capillary force from the start zone (24; 24?) to the target zone (26, 28; 26a-e). The conduction zone has a multiplicity of open flow channels separated from one another by microporous bridges having open-pored side walls.

Abstract: The present invention addresses the mechanistic role of Lipin1 in the absence of embryonic development. Accordingly, the present invention relates to novel Lipin1 polypeptides and nucleic acids encoding these polypeptides, which polypeptides are involved in body-weight regulation, energy homeostasis, metabolism, obesity, and diabetes. Furthermore, the invention provides substances modulating the function of the polypeptides of the invention, in particular siRNAs inhibiting Lipin1 function in general and Lipin1B2 function in particular and the medical uses of Lipin1 activators and inhibitors.